ABILITYPHARMA

AbilityPharma is a clinical stage phase 2b/3 biopharmaceutical company focused on autophagy to treat cancer

PIPELINE

ABTL0812, first-in-class, is currently in phase 2b/3 clinical trials in pancreatic cancer in Spain, USA, France, and Israel. The product has also completed with positive results a phase 2a trial in endometrial cancer and lung cancer in Spain and France. 

SCIENCE

AbilityPharma investigates cancer drugs inducing cytotoxic autophagy selectively in cancer cells

AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cancer cell death. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.

Media Center

28.12.2020

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020

Press Release

The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
29.12.2020

In the media

The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million + info
29.12.2020

In the media

The Chinese SciClone enters at the biotech Ability Pharma + info
February

Events

LSX World Congress + info
March

Events

BIO-Europe Spring. Digital + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG